Treating the eye area can produce significant improvements for patients, but it also carries a level of responsibility that few other areas of aesthetic practice can match.
From botulinum toxin and dermal fillers to polynucleotides, plasma fibroblast treatments, chemical peels, threads, and energy-based devices, the range of procedures carried out around the eyes continues to grow. But when a complication affects vision, eyelid function, or causes permanent scarring in a highly visible area, the consequences for both patient and practitioner can be serious.
In our companion article, Seeing the whole picture: Eye health and aesthetic safety, we explore the clinical risks associated with periorbital treatment. Here, we look specifically at the insurance and liability considerations: what practitioners need to check before treating, why documentation matters, and what to do when a patient raises a concern.
All aesthetic treatments carry risk, but claims involving the eye area can be particularly complex.
The first reason is severity. A filler-related vascular occlusion can, in rare cases, lead to visual impairment or blindness. Other procedures may result in corneal injury, burns, scarring, persistent swelling, asymmetry, or changes to eyelid position and function. Where an injury is permanent or affects a patient’s sight, the potential financial and personal consequences can be substantial.
The second is complexity. Establishing what happened may need evidence from specialist clinicians, including ophthalmologists, alongside a detailed review of the practitioner’s consultation, technique, records, aftercare, and response to the complication. This can make claims costly to investigate and defend, even where the practitioner disputes that treatment was negligent.
Complaints may also arise from less severe outcomes. The eye area is highly visible and patients may be particularly sensitive to asymmetry, prolonged swelling, changes in expression, or an outcome that does not match their expectations. Tear trough filler, for example, can lead to concerns about puffiness, contour irregularities, or product visibility, while botulinum toxin treatment may prompt complaints about eyelid or brow position.
There is also a reputational dimension. A visible complication can affect a patient’s confidence and may quickly lead to negative reviews or social media posts. How the practitioner communicates and responds in the early stages can therefore have a significant impact on what happens next.
Before carrying out any treatment in or around the eye area, check your policy schedule carefully.
A medical malpractice insurance policy protects the insured against allegations of negligence arising from the advice they give, the treatment or procedure they carry out, or the product they use, where this results in bodily injury to a patient. But cover is not automatically universal across every aesthetic procedure.
Your policy schedule sets out the treatments or procedures covered by your insurance. If a treatment is not listed, you should not assume that it falls under a broad description such as ‘injectables’ or ‘facial aesthetics’.
This becomes particularly important as the periorbital treatment menu expands. Dermal fillers, botulinum toxin, polynucleotides, thread lifting, plasma fibroblast treatments, chemical peels, and laser or other energy-based procedures are different treatment categories with different risk profiles.
Practitioners should also consider:
Off-label use needs particular care. ‘Off-label’ generally means using a licensed medicine outside the terms of its marketing authorisation. Practitioners should be precise about what is being used off-label, why, whether this falls within their scope of practice, and whether their insurer needs to be told.
If you are adding a new eye-area treatment, changing device, or introducing a different procedure, speak to your insurer before treating your first patient. Hamilton Fraser also recommends checking your policy schedule whenever your treatment menu changes.
Good records matter in every aesthetic claim, but they can be particularly important in the periorbital area.
Many patients have some degree of natural facial asymmetry before treatment. Differences in brow height, eyelid position, tear trough depth, swelling, and skin laxity may only become a point of dispute after a procedure. Without clear baseline photographs and assessment notes, it can be difficult to establish what was present beforehand.
A strong patient record should include:
For dermal filler treatment in areas where there is a risk of visual complications, consent should reflect the serious risks that a reasonable patient would want to know about. A signature on a generic form is unlikely to tell the full story of the consultation. The notes should show what was discussed, how risks were explained, and that the patient had an opportunity to ask questions.
Read more in our guides to best practice in patient consent and keeping accurate, high-quality photo records.
A practitioner does not need to receive a solicitor’s letter before contacting their insurer.
A patient reporting a significant complication, threatening legal action, asking for compensation, or making allegations about their treatment may all indicate a potential claim. Under a ‘claims made’ medical malpractice policy, practitioners need to tell their insurer about circumstances that may give rise to a claim in line with the policy terms.
Early notification gives the claims team more opportunity to understand what has happened and give appropriate support.
If a concern arises:
There is an important distinction between responding with care and admitting liability. Practitioners can acknowledge a patient’s concerns, arrange review, and support appropriate clinical care without making statements about legal responsibility before the facts have been assessed.
Our guide, Behind the scenes of a claim: What is the process?, explains what practitioners can expect after notifying Hamilton Fraser. You can also read our advice on complaints and claim handling.
Reviewing your exposure now, before a complaint arises, is worth doing. Practical steps include checking your current policy schedule against your treatment menu, auditing consent documents, reviewing photography standards, and testing your complication protocols.
For practitioners carrying out hyaluronic acid filler treatment in higher-risk facial areas, this should include checking that appropriate emergency resources, including hyaluronidase, are immediately available and that the team knows how to respond to suspected vascular compromise or visual symptoms.
Treatment records should also be detailed enough for another suitably qualified person to understand what happened months or even years later. If you could not reconstruct the consultation, treatment, products used, advice given, and follow-up from the notes alone, there may be gaps worth dealing with now.
And if you plan to add a new periorbital procedure, contact Hamilton Fraser before you start treating. Do not assume that existing cover extends automatically to a new product, device, technique, or treatment category.
Ocular aesthetics brings together clinical complexity, high patient expectations, and the potential for serious complications. For practitioners, managing that risk means looking beyond technical skill alone.
The right insurance cover, a current and accurate policy schedule, clear consent, strong photographic and clinical records, careful communication, and early notification of potential claims all help to protect your position.
The eye area leaves little room for assumptions. Knowing what you are covered to do, documenting why and how you treated, and having a clear plan when concerns arise can make a significant difference for both the patient and the practitioner.
Find out how Hamilton Fraser can support you. Get in touch with our team today.
